Johnson & Johnson (NYSE: JNJ) delivered stronger-than-expected second-quarter 2026 results, prompting management to raise its full-year outlook as new pharmaceutical launches and sustained demand for key therapies fueled revenue growth. The healthcare giant continued to demonstrate the resilience of its diversified business model despite increasing competitive pressure from biosimilars.

The results reinforce the strength of Johnson & Johnson’s pharmaceutical franchise at a time when global healthcare companies are balancing patent expirations with significant investments in next-generation medicines. For investors worldwide, including those following healthcare markets from Israel, the company’s performance highlights the growing importance of innovation in sustaining long-term earnings growth.

Second-Quarter Beat Supports Higher Full-Year Guidance

Johnson & Johnson reported worldwide sales of $25.3 billion during the second quarter, representing 5.6% operational growth compared with the same period last year. The company also posted adjusted earnings per share of $2.90, exceeding market expectations on both revenue and profitability.

Chairman and Chief Executive Officer Joaquin Duato described 2026 as a year of accelerated growth, noting that the company delivered a beat on both the top and bottom lines while raising its financial outlook. Excluding the impact of STELARA, Johnson & Johnson reported double-digit operational growth, illustrating the strength of its broader pharmaceutical portfolio.

The improved outlook reflects management’s confidence that recently launched therapies and continued commercial execution will more than offset revenue pressure from products facing patent expiration and biosimilar competition.

Innovative Medicine Continues to Drive Growth

The company’s Innovative Medicine segment remained the clear growth engine during the quarter. Oncology treatments including DARZALEX, CARVYKTI, TECVAYLI, and TALVEY continued generating robust sales, while immunology treatment TREMFYA delivered a major milestone by recording its first-ever $2 billion quarter.

Newer therapies, including ICOTYDE and INLEXZO, also contributed meaningfully as Johnson & Johnson expands its next generation of growth products. These successful launches are increasingly important as the company works to replace revenue lost from mature products.

Meanwhile, STELARA continued experiencing significant sales declines following the entry of biosimilar competitors. Nevertheless, management emphasized that the broader Innovative Medicine portfolio has successfully absorbed much of this pressure through diversified growth across multiple therapeutic areas.

MedTech Faces Mixed Conditions While Cash Generation Remains Strong

Johnson & Johnson’s MedTech business produced a more mixed performance. Cardiovascular operations experienced slower growth, with electrophysiology and the Abiomed business weighing on segment results. However, several other businesses—including surgery, vision, and orthopedics—showed improving momentum during the quarter.

Despite uneven growth across medical devices, management reaffirmed expectations of generating approximately $21 billion in free cash flow during 2026. Strong cash generation continues supporting research and development, shareholder returns, acquisitions, and continued investment in the company’s global product pipeline.

The diversified combination of pharmaceuticals and medical technology remains one of Johnson & Johnson’s competitive strengths, providing multiple sources of revenue while reducing dependence on any single product category.

Looking ahead, investors will closely monitor the commercial performance of Johnson & Johnson’s newest therapies, continued adoption of flagship oncology and immunology treatments, and the pace of revenue replacement as biosimilar competition intensifies. Additional product approvals, clinical trial milestones, and continued execution across the MedTech business will likely determine whether the company can sustain its accelerated growth trajectory throughout the remainder of 2026. With a diversified portfolio, robust cash generation, and an expanding pipeline, Johnson & Johnson remains well positioned to navigate an increasingly competitive global healthcare landscape.